Rivaroxaban Shown to Cut Risk of Cardiovascular EventsRivaroxaban (Xarelto, Janssen/ Bayer) has been found to significantly reduce the risk of strokes and heart attacks in patients with artery disease.
Patient and Physician Education Boosts Anticoagulant Adherence RatesEducation about anticoagulants helped boost adherence rates and led to a small decrease in stroke risk.
Anticoagulation in AF: More than just a risk score?At the 2015 AHA Fall Conference, Daniel E. Singer, MD, spoke about the current shortcomings of atrial fibrillation guidelines that use the CHADS-VASc score.
How to identify AF patients at low stroke riskIn a presentation at the 2015 AHA Fall Conference, Daniel E. Singer, MD, spoke about identifying patients with an increased bleeding risk with the long-term use of oral anticoagulants and whether or not there is a benefit in those cases.
Major safety concerns with top-selling prescription drugsMajor safety concerns exist for many top-selling prescription drugs including benzodiazepines/prescription sleep aids, anticoagulants, cholesterol-lowering statins, oxycodone and hydrocodone, and stimulants. The following provides an overview of these classes and issues.
Edoxaban: An oral inhibitor of factor Xa
New data: Hospital readmission among NVAF hospitalized patients treated with new oral anticoagulantsData from a real-world analysis provided an early view of hospital readmissions among hospitalized nonvalvular atrial fibrillation (NVAF) patients treated with new oral anticoagulants (NOACs).
ACC: NVAF patients at high risk for stroke may be undertreatedMany nonvalvular atrial fibrillation (NVAF) patients at high risk for stroke may be undertreated, according to poster presentation sessions at the American College of Cardiology (ACC) 64th Annual Scientific Session in San Diego, Calif.
Fondaparinux beats heparin in major studyThe anticoagulant medication Fondaparinux (Arixtra) was associated with reduced major bleeding events and improved survival, compared to low-molecular-weight heparin (LMWH) in a large randomized clinical trial involving patients with non–ST-segment elevation myocardial infarction (NSTEMI), according to a new study.
Factor Xa inhibitor approved to reduce stroke risk in AF patientsThe factor Xa inhibitor edoxaban (Savaysa, Daiichi Sankyo) has been approved by FDA to lower the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF).